Transurethral microwave thermotherapy: an evolving technology in the treatment of benign prostatic enlargement

Contains fulltext : mmubn000001_231449461.pdf (publisher's version ) (Open Access)Promotores : F. Debruyne en J. de la Rosette191 p

Transurethral microwave thermotherapy : an evolving technology in the treatment of benign prostatic enlargement

Contains fulltext : 21401.PDF (publisher's version ) (Open Access

High-energy transurethral microwave thermotherapy: a thermoablative treatment for benign prostatic obstruction

Contains fulltext : 24015___.PDF (publisher's version ) (Open Access

Experience with the Ultraline and Urolase laser fibers :is there any difference?

Contains fulltext : 22006___.PDF (publisher's version ) (Open Access

High energy thermotherapy in the treatment of benign prostatic hyperplasia: results of the European Benign Prostatic Hyperplasia Study Group

Contains fulltext : 24014___.PDF (publisher's version ) (Open Access

Correlation between uroflowmetry, prostate volume, postvoid residue, and lower urinary tract symptoms as measured by the International Prostate Symptom Score

Contains fulltext : 23597___.PDF (publisher's version ) (Open Access

Urodynamic assessment in the laser treatment of benign prostatic enlargement

Contains fulltext : 21442.PDF (publisher's version ) (Open Access

A 12-month study of the placebo effect in transurethral microwave thermotherapy

Contains fulltext : 23444.PDF (publisher's version ) (Open Access

Computerised assessment of maximum urinary flow: An efficient, consistent and valid approach

Objectives: To evaluate the relative accuracy of a computerised method to quantitatively assess maximum urinary flow. Methods: A total of 1147 uroflows were evaluated by the computerised method and by three experts from different European countries. The sample consisted of uroflows from the respective visits by a 20% sample of randomly chosen patients (n = 223) with lower urinary tract symptoms with participation in two clinical trials in which the efficacy and safety of Permixon was evaluated. The proportions of automated maximum flow values included in the 10% extended range of experts (and their 95% confidence intervals) were assessed, as well as the concordance coefficients between experts and the computerised method and the paired Student's t-test for the average differences between experts and computer. Results: The rate of agreement between experts and computer varied between about 95 and 100% over factor levels for visit, type of machine and country. Concordance coefficients indicated good agreement between experts and the automated method. When looking at average differences between experts and the computer, the smallest differences were observed between experts 2, 3 and the computer (differences not statistically significant). Statistically significant average differences were observed between expert 1 and the other experts as well as between expert 1 and the computer. Conclusions: The computerised assessment decreases the fraction of variability of maximum urinary flow caused by artifacts as well as intra- and inter-expert variation. The computerised assessment of maximum urinary flow is an efficient, consistent and valid approach to quantitatively assess maximum urinary flow in clinical trials. © 2002 Elsevier Science B.V. All rights reserved.SCOPUS: ar.jinfo:eu-repo/semantics/publishe